NATICK, Mass., Oct. 10 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX) today announced it has received approval from the
U.S. Food and Drug Administration (FDA) to market its second-generation
TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary Stent System. The Company
plans to launch the TAXUS Liberte stent early next month in the United
States, following completion of the introduction of its TAXUS(R)
Expresss2(TM) Atom(TM) Paclitaxel-Eluting Coronary Stent System, which was
approved by the FDA last month. The TAXUS Liberte stent was launched in
Europe and other international markets in 2005.
To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/bsci/34446/
"The TAXUS Liberte stent represents our latest advance in drug-eluting stent technology," said Donald Baim, M.D., Chief Medical and Scientific Officer of Boston Scientific. "This device has substantially thinner struts and a more flexible cell geometry for improved deliverability, as well as uniform strut distribution designed specifically for drug elution. The TAXUS Liberte stent demonstrated similar late loss and target vessel revascularization (TVR) as the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System in the ATLAS Workhorse clinical trial, despite treating more challenging patients."
"We believe the approval of TAXUS Liberte is a clear indication that we have made significant progress toward resolving the issues related to the Corporate Warning Letter," said Jim Tobin, President and Chief Executive Officer of Boston Scientific.
The TAXUS stent systems -- both Liberte and Express2 -- have been
evaluated by the industry's most
|SOURCE Boston Scientific|
Copyright©2008 PR Newswire.
All rights reserved